A group of clinics cooperating as the Lupus Plasmapheresis Study Group (LPSG) is starting an international multicenter study of the treatment of severe systemic lupus erythematosus. The primary goal of this randomized and prospective trial is to establish whether treatment with plasmapheresis and subsequent pulse cyclophosphamide improves the outcome compared to treatment with pulse cyclophosphamide alone.
The underlying rationale assumes that plasmapheresis: a) eliminates pathogenic autoantibodies and immune complexes and b) induces a compensatory activation of pathogenic lymphocyte clones through a feedback between circulating antibodies and their respective antibody-producing clones. Synchronization of plasmapheresis with subsequent pulse cyclophosphamide should enhance the deletion of pathogenic clones during the period of greatest vulnerability.
This overview reviews the first results of treatment approaches based on this concept and summarizes the design of the LPSG trial
ReveilleJ.D., BarolucciA., AlarcónG.S.Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death.Arthritis Rheum1990; 33: 37–48.
2.
KlippelJ.H.Survival in SLE.Proc Int Conf SLE1990; 2: 187–9.
3.
AustinH.A., KlippelJ.H., BalowJ.E.Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.N Engl J Med1986; 314: 614–9.
4.
SteinbergA.D., LindahlM., GourleyM., ScottD., SteinbergS.C.Approach to lupus nephritis based upon randomized trials.Proc Int Conf SLE1990; 2: 206–9.
5.
GibbonsR.B., WestermannE.Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide in the treatment of lupus nephritis.Arthritis Rheum1988; 31: 1552–4.
6.
KlippelJ.H.Systemic lupus erythematosus. Treatment-related complications superimposed on chronic disease.J Am Med Ass1990; 263: 1812–5.
7.
NIH Conference, BaloxJ.E., AustinH.A.Lupus nephritis.Ann Int Med1987; 106; 79–94.
8.
KlippelJ.H.Immune suppression in the treatment of SLE.Proc Int Conf SLE1989; 2: 200–2.
9.
McCuneW.J., GolbusJ., ZeidesW., BohlkeP.P., DunneR., FoxD.A.Clinical and immunological effects of monthly administration of intravenous cyclophosphamide.N Engl J Med1988; 318: 1423–31.
10.
BoumpasD.T., BarezS., KlippelJ.H., BalowJ.E.Intermittent cyclophosphamide for the treatment of automimmune thrombopenia in systemic lupus erythematosus.Ann Int Med1990; 112: 674–7.
11.
JonesJ.V., BucknallR.C., CummingR.H., AsplinC.M.Plasmapheresis in the management of systemic lupus.Lancet1976; 2: 709–11.
12.
GayraudM., GuillevinL., SobelA.Traitement du lupus systémique sévère par corticoides; immunosup-presseurs et échanges plasmatique.Sem Hop Paris1986; 62: 453–8.
13.
KofflerD., AgnelloV., ThoburnR., KunkelH.G.Systemic lupus erythematosus: prototype of immune complex nephritis in man. Pathophysiology of circulating immune complexes.Arthritis Rheum1982; 27: 783–7.
14.
TheofilopoulosA.N., DixonF.J.The biology and detection of immune complexes.Adv Immunol1979; 28: 89–220.
15.
LockwoodC.M., WorlledgeS., NicholasA., CottonC., PetersD.K.Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange.N Engl J Med1979; 300: 524–30.
16.
LowA., HotzeA., KrapfF.The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis.Rheumatol Int1985; 5: 69–72.
17.
BystrynJ.C., GrafM.W., UhrJ.W.Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion.J Exp Med1970; 132: 1279–87.
18.
BystrynJ.C., SchenkheinI., UhrJ.W.A model for regulation of antibody synthesis by serum antibody. In: ArnosB., ed. Progress in immunology.New York: Academic Press, 1971; 627–36.
19.
JonesJ.V., CummingR.H., BaconP.A.Evidence for a therapeutic effect of plasmapheresis.Q J Med1979; 48: 555–76.
20.
JonesJ.V.Plasmapheresis in SLE.Clin Rheum Dis1982; 8: 243–60.
21.
SchlanskyR., deHoratiusR.J., PincusT., TungK.S.K.Plasmapheresis in systemic lupus erythematosus. A cautionary note.Arthritis Rheum1981; 24: 49–53.
22.
KrapfF., ManagerB., KockB., KrauledatP., KaldenJ.R.The estimation of circulating immune complexes, C3d, and anti-ds-DNA-antibody serum levels in the monitoring of therapeutic plasmapheresis in a patient with systemic lupus erythematosus.Clin Exp Rheumatol1985; 3: 159–62.
23.
WeiN., KlippelJ.H., HustonD.P.Randomised trial of plasma exchange in mild systemic lupus.Lancet1983; 1: 17–22.
24.
CloughJ., LewisE., LachinJ.The Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis as adjunct to conventional therapy in severe lupus nephritis. Abstracts of the 2nd International Congress of the WAA 1988; S-2-1.
25.
Belghiti-DeprezD., SobelP.A controlled trial of plasma exchange in severe acute systemic lupus erythematosus. In: Immunointervention in autoimmune diseases. Abstracts. Paris: Maison de la Chimie, 1988.
26.
SchroederJ.O., EulerH.H.Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. In: HörlW.H., SchollmeyerP.J., eds. New perspectives in hemodialysis, peritoneal dialysis, arteriovenous hemofiltration, and plasmapheresis.New York, London: Plenum Press, 1989; 203–13.
27.
EulerH.H., SchroederJ.O., LöfflerH.The antibody rebound as a rationale for synchronizing plasmapheresis with pulse cytotoxic drugs. In: OdaT., ShiokawaY., InoueN., eds. Proceedings of the First International Congress of the World Apheresis Association: Therapeutic Plasmapheresis VI.Cleveland: ISAO-Press, 1987; 200–7.
SchroederJ.O., EulerH.H., LöfflerH.Synchronization of plasmapheresis and pulse cyclophosphamide in severe lupus erythematosus.Ann Int Med1987; 107: 344–6.
30.
EulerH.H., LöfflerH., ChristophersE.Synchronization of plasmapheresis and pulse cyclophosphamide in pemphigus vulgaris.Arch Dermatol1987; 123: 1205–10.
31.
ZielinskiC., MuellerC., SmolenJ.Plasmapheresis in the treatment of systemic lupus erythematosus: a controlled study.Acta Med Austriaca1988; 15: 155–8.
32.
BarrW.G., HubbelE.A., RobinsonJ.A.Plasmapheresis and pulse cyclophosphamide in systemic lupus erythematosus.Ann Int Med1987; 108: 152–3.
33.
HustonD.P., BresslerR.B., SukiW.N., HustonM.M., AndrewS.L., KavanaughA.F.A controlled trial of pulse cyclophosphamide and plasmapheresis therapy of lupus nephritis (Abstract).Arthritis Rheum1988; 31(suppl): 55.
34.
LiangM.H., SocherS.A., RobertsW.N., EsdaileJ.M.Measurement of systemic lupus erythematosus activity in clinical research.Artritis Rheum1988; 31: 817–25.
35.
LiangM.H., SocherS.A., LarsonM.G., SchurP.H.Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.Arthritis Rheum1989; 32: 1107–18.
36.
WallaceD.J., GoldfingerD., SavageG.Predictive value of clinical, laboratory, pathologic, and treatment variables in steroid/immunosuppressive resistant lupus nephritis.J Clin Apheresis1988; 4: 30–4.
37.
PizzoP.A., AmstrongD., BodeyG.The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient.J Inf Dis1990; 161: 397–401.
38.
TanE.M., CohenA.S., FriesJ.F.The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum1982; 25: 1271–7.
39.
Committee on Prognosis Studies.Prognosis studies in SLE: an activity index (Abstract).Arthritis Rheum1986; 29 (Suppl.): S93.
40.
IsenbergD., BaconP., BombardierC.Criteria for assessing disease activity in systemic lupus erythematosus.J Rheumol1989; 16: 1395–6.
41.
French Cooperative Study Group.A randomised trial of plasma exchange in severe acute systemic lupus erythematosus: methodology and interim analysis.Plasma Ther Transfus Technol1985; 6: 535–9.
MorrowW.J.W., IsenbergD.A., Todd-PokropekA., ParryH.F., SnaithM.L.Useful laboratory measurements in the management of systemic lupus erythematosus.Q J Med1982; 202; 125–38.
44.
SymmonsD.P.M., CoppockJ.S., BaconP.A.Development and assessment of a computerised index of clinical disease activity in systemic lupus erythematosus.Q J Med1988; 258: 927–37.
